Scisparc Ltd. · NASDAQ:SPRC
Scisparc — Therapix Biosciences — IPO Roadshow (October 2020)
24 slides from Scisparc's IPO roadshow presentation, Oct 21, 2020
Slide 1: Developing Cannabinoid Based Pharmaceuticals Investor Presentation
Developing C annabinoid B ased P harmaceuticals Investor Presentation • October 2020 1 Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated October 21 , 2020 Relating to the Preliminary Prospectus dated October 21 , 2020 Registration Statement File No. 333 -
Slide 2: Free Writing Prospectus Statement
Free Writing Prospectus Statement This presentation highlights basic information about us and the offering to which this presentation relates. Because it is a summary, it does not contain all of the information that you should consider before investing in our securities. The Company has filed a Regi
Slide 3: Safe Harbor Statement
Saf e Harbo r Statement This presentation of Therapix Biosciences Ltd . (the “ Company ” ) contains “ forward - looking statements ” within the meaning of the Private Securities Litigation Reform Act and other securities laws . Words such as “ expects, ” “ anticipates, ” “ intends, ” “ plans, ” “ be
Slide 4: The Offering
Issuer Therapix Biosciences Ltd. Deal Size $15,000,000 Proposed Symbol NASDAQ: TRPX Offering Type IPO / Uplist Unit Description 1 ADS, 2 Warrants to purchase 1 ADS each Units Offered 2,500,000 Unit Price Range $ 5 - $ 7 Use of Proceeds Repayment of $1.5 million of debt to a shareholder and amounts d
Slide 5: Our Vision
To bridge cannabis and cannabinoids to the healthcare system to improve the health and wellbeing of patients OUR VISION 5
Slide 6: Therapix Company Highlights
• D eveloping cannabinoid - based therapies • Science driven and targeted treatment solutions • New, committed experienced managment • Entourage Effect seeks to increase efficiency, lower dosage and side effects • Our intellectual property portfolio comprises three granted U.S. patents and pending p
Slide 7: The Therapix Story
The Therapix S tory Therapix is a s pecialty p harmaceutical c ompany focused on repurposing approved c annabinoids for new indications Platform Programs THX - 110 An innovative and proprietary drug candidate platform based on FDA approved THC, for the treatment of Central Nervous System diseases su
Slide 8: The Entourage Effect
T h e “ Entourag e Effect ” The "Entourage Effect", first described by Prof. Raphael Mechoulam in 199 8 1 Effects of the Endocannabinoid system can be explained by its overall constituents working together, synergistically, rather to any single component The Entourage technology is the basis of all
Slide 9: The Entourage Effect: Therapix Platform
“ The Entourage Effect “ Therapix Platform Increased Efficiency, Lower Dosage and Side Effects Therapix ’ s proprietary combination of CannAmide TM and any Cannabinoid creating an “ Entourage Effect ” , first discovered by Prof. Raphael Mechoulam in 1998 , which results in synergy. CannAmide TM Form
Slide 10: Dosage regimen compromises therapeutic benefits of cannabis
Dosage regiment compromises therapeutic benefits of cannabis and severely impacts treatment • Serious diminishing effect over time and extensive use • High doses lead to unwanted adverse events • Compromises therapeutic benefits of cannabis and severely impacts treatment We believe that reducing med
Slide 11: Tourette Syndrome Disease Overview
Disease Overview • TS is a movement and neurobehavioral disorder characterized by motor and vocal chronic tics with onset before age 18 • About half to two - thirds of the cases get much better during adolescence 1 • However adults will generally be more severe patients 2 • Tics may be associated wi
Slide 12: Tourette Syndrome Phase IIa Clinical Trial
Tourette Syndrome Phase IIa Clinical Trial THX - 110 S: Seeking to Provide Increased Efficiency, Lower Dosage and Side Effects Tourette syndrome is a movement and neurobehavioral disorder characterized by motor and vocal tics and is highly linked with co - morbidities We believe that topline results
Slide 13: Tourette Syndrome Phase IIb Clinical Trial
Joint Pharma Tourette Syndrome Phase IIb Clinical Trial • Therapix intends to evaluate the efficacy, safety and tolerability of its THX - 110 C (Full Cannabis Extract (FCE) with CannAmide TM ) in a randomized, placebo - controlled trial • The study is expected to commence in at least on center in Ha
Slide 14: THX-110 for Obstructive Sleep Apnea
THX - 110 s for OBSTRUCTIVE SLEEP APNEA THX - platform: Seeking to Provide Increased Efficiency, Lower Dosage and Side Effects OSA causes breathing to repeatedly stop during sleep and is a potentially lethal sleep disorder. There are currently no FDA approved pharmaceutical therapies to treat
Slide 15: Obstructive Sleep Apnea (OSA)
Obstructive Sleep Apnea (OSA) • Of the 10 patients recruited into the study, nine patients have completed the study and one has dropped out of the study due to treatment associated adverse event (dizziness) • Among the remaining nine patients, 55 % demonstrated significant improvement in Apnea – Hyp
Slide 16: THX-210 for Autism
PEA Significantly Increases CBD Effects 1 • CBD was shown to prevent fat accumulation in liver cells in a concentration dependent manner • PEA by itself didn ’ t affect fat accumulation • Addition of PEA to CBD reduced the required CBD concentration while achieving maximal effect THX - 210 for Autis
Slide 17: THX-160 for Pain
1 • An innovative and proprietary CB 2 Receptor Agonist formulation intended for the treatment of pain. This specific CB 2 receptor agonist was synthesized by Professor Raphael Mechoulam, Ph.D. • THX - 160 , a synthetic CB 2 Receptor Agonist, which is protected under patent granted in the US and Eur
Slide 18: CannAmide
CannAmide ™ CannAmide TM (TheraPEA) – For pain and inflammation: Active ingredient Palmitoylethanolamide – Endocannabinoid - like compound, a lipid - messenger and an endogenous neuromodulator with a broad spectrum of pharmacological properties and can be found naturally in the body, as well as in e
Slide 19: Pipeline
Pipe l ine COMPOUND THX – 110 THERAPEUTIC AREA PRECLINICAL Medical Cannabis route PHASE IIa PHASE IIb TOURETTE SYNDROME OBSTRUCTIVE SLEEP APNEA THX – 110 THX – 210 Autism THX – 160 Pain THX - 110 – Full Cannabis Extract (FCE) with CannAmide TM for the treatment Tourette ’ s Syndrome and Obstructive
Slide 20: Highlights
Highlights 20 • We believe that we have u nique technologies in the cannabis market • Focus on cannabinoid family products with unique combinations, methods of administrations and formulations • Pursuing new high potential R&D and clinical programs through M&A • Advanced clinical programs • CannAmid
Slide 21: Therapix Management
Joint Pharma Therapix Management Adi Zuloff - shani , PhD, CTO Dr. Adi Zuloff - Shani has served as our Chief Technologies Officer since February 2016 . Dr. Zuloff - Shani is a Research & Development professional with overall experience of about 20 years in the bio - tech and healthcare industry. Dr
Slide 22: Directors
Lior Amit , Director Mr. Amit serves as a consultant to both private and public companies as well as individuals. Mr. Amit serves as director of ScoutCam Inc., Matomy Ltd., Nirplex Ltd., Ronimar Ltd., Endemol Israel Ltd. and B.S.S.CH. - The Israeli Credit Insurance Company Ltd. Mr. Amit previously s
Slide 23: Scientific Advisory Board
Therapix Biosciences Scientific Advisory Board Active Scientists Endocannabinoids and PEA Pain CNS Dr. Michael Bloch Prof. James Leckman Prof. Raphael Mechoulam Prof. Avi Weizman Prof. Kirsten Muller - Vahl Prof. Michael Davidson Prof. Elon Eisenberg Dr. Daniele Piomelli Prof. Saoirse. O'Sullivan Dr
Slide 24: Thank You
THERAPIX BIOSCIENCES THANK YOU